Relevant Interviews, Disease and Trial Updates and Stock-Markets News posted by CRISPR Medicine News.

Check also Companies to Follow in 2022 and CMN Markets for the latest stock and market trends.

Always stay updated with the free CMN Newsletter.

Precision Biosciences

Main focus: Gene editing for the treatment of genetic diseases and cancer

Company stage: Clinical

Diseases: Non-hodgkins lymphoma (NHL), multiple myeloma, B-cell acute lymphoblastic leukaemia (ALL), chronic lymphocytic leukaemia (CLL), small lymphocytic lymphoma (SLL), Duchenne muscular dystrophy, primary hyperoxaluria type 1, chronic hepatitis B infection.

Genome editing tool: megaNuclease

Funding stage: Public (NASDAQ:DTIL)

Location: Durham, North Carolina, US



Partners: Eli Lilly, SpringWorks Therapeutics, iECURE

Precision Biosciences utilises its proprietary ARCUS genome-editing plaform to develop novel CAR-T and gene-editing therapies. The platform is based on the homing endonuclease I-CreI that allows for single, highly specific DNA edits. The company has advanced multiple CAR-T programmes to clinical trials, mainly for the treatment of haematological cancers. Furthermore, the company has a broad in vivo gene correction pipeline under development for the treatment of genetic diseases.


HashtagPrecision BioSciences, Inc.

Company: Precision Biosciences
Jobs, banner ads, webinars, sponsored content...
Search CRISPR Medicine